JAK2 and myeloproliferative disorder: In addition, in the univariate but not in the multivariate analysis, more than 84.7 TF+MPs per microliter and the presence of documented CV risk (not expressed by the presence of the JAK2 V617F mutation, sex or age >60 years) predicted the development of thrombosis in MPN subjects (p = 0.02 for both) [26].